4.6 Article

Oxidized low density lipoprotein in the liver causes decreased permeability of liver lymphatic- but not liver sinusoidal-endothelial cells via VEGFR-3 regulation of VE-Cadherin

期刊

FRONTIERS IN PHYSIOLOGY
卷 13, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2022.1021038

关键词

lymphatic endothelial cell; liver sinusoidal endothelial cell; alcohol-associated liver disease; cholestasis; non-alcoholic fatty liver disease; VE-cadherin; vascular endothelial growth factor; oxidized low density lipoprotein

资金

  1. NIH [R01 AI121209, R01 AI155474, R21 AI155929, R01 DK125595]
  2. Department of Medicine Outstanding Early Career Scholar
  3. RNA Biosciences Initiative Clinical Scholar Award
  4. University of Colorado Anschutz Medical Campus GI and Liver Innate Immune Programs
  5. Waterman Family Foundation for Liver Research
  6. Ruth L. Kirschstein National Research Service Award Institutional Research Training Grant [T32 DK067009, R00AA02385]

向作者/读者索取更多资源

This study investigates the impairment of liver lymphatic function in chronic liver diseases and its underlying mechanisms. The findings suggest that chronic liver diseases, such as NAFLD, ALD, and PSC, lead to impaired lymphatic drainage and increased levels of oxLDL. Furthermore, the study demonstrates that oxLDL decreases the permeability of lymphatic endothelial cells through the regulation of SRC-family kinases, MAPK kinase, and VE-Cadherin. The engagement of VEGFR-3 by its ligands prevents the upregulation of VE-Cadherin and improves lymphatic permeability.
The lymphatic vasculature of the liver is vital for liver function as it maintains fluid and protein homeostasis and is important for immune cell transport to the lymph node. Chronic liver disease is associated with increased expression of inflammatory mediators including oxidized low-density lipoprotein (oxLDL). Intrahepatic levels of oxLDL are elevated in nonalcoholic fatty liver disease (NAFLD), chronic hepatitis C infection (HCV), alcohol-associated liver disease (ALD), and cholestatic liver diseases. To determine if liver lymphatic function is impaired in chronic liver diseases, in which increased oxLDL has been documented, we measured liver lymphatic function in murine models of NAFLD, ALD and primary sclerosing cholangitis (PSC). We found that Mdr2-/- (PSC), Lieber-DeCarli ethanol fed (ALD) and high fat and high cholesterol diet fed (NAFLD) mice all had a significant impairment in the ability to traffic FITC labeled dextran from the liver parenchyma to the liver draining lymph nodes. Utilizing an in vitro permeability assay, we found that oxLDL decreased the permeability of lymphatic endothelial cells (LEC)s, but not liver sinusoidal endothelial cells (LSEC)s. Here we demonstrate that LECs and LSECs differentially regulate SRC-family kinases, MAPK kinase and VE-Cadherin in response to oxLDL. Furthermore, Vascular Endothelial Growth Factor (VEGF)C or D (VEGFR-3 ligands) appear to regulate VE-Cadherin expression as well as decrease cellular permeability of LECs in vitro and in vivo after oxLDL treatment. These findings suggest that oxLDL acts to impede protein transport through the lymphatics through tightening of the cell-cell junctions. Importantly, engagement of VEGFR-3 by its ligands prevents VE-Cadherin upregulation and improves lymphatic permeability. These studies provide a potential therapeutic target to restore liver lymphatic function and improve liver function.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据